From Wikipedia, the free encyclopedia
  (Redirected from LY293111)
Jump to: navigation, search
Etalocib structure.png
CAS number 161172-51-6 N
PubChem 177941
ChemSpider 154905 YesY
KEGG D04074 YesY
Jmol-3D images Image 1
Molecular formula C33H33FO6
Molar mass 544.61 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N (verify) (what is: YesY/N?)
Infobox references

Etalocib is a drug under development for the treatment of various types of cancer, for example non-small-cell lung carcinoma[1] and pancreatic cancer. It acts as a leukotriene B4 receptor antagonist and a PPARγ agonist.[2]


  1. ^ Jänne, P. A.; Paz-Ares, L; Oh, Y; Eschbach, C; Hirsh, V; Enas, N; Brail, L; von Pawel, J (2014). "Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer". Journal of Thoracic Oncology 9 (1): 126–31. doi:10.1097/JTO.0000000000000037. PMID 24346102.  edit
  2. ^ Adrian, T. E.; Hennig, R; Friess, H; Ding, X (2008). "The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer". PPAR Research 2008: 827096. doi:10.1155/2008/827096. PMC 2631651. PMID 19190780.  edit